Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 25, 2015
Pharmacy Choice - News - Generic Drugs - November 25, 2015

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 45     Next >>     Go To Page:

11/25/15 - Teligent Completes Acquisition of Alveda Pharmaceuticals' Assets
By a News Reporter-Staff News Editor at Telecommunications Weekly Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced it has completed the acquisition of the assets of Alveda Pharmaceuticals, Inc. for $47 million CAD in cash. Announced in October 2015, the accretive transaction provides Teligent a platform to e
11/24/15 - Amphastar Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference
Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 27 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 11:30 a.m. Eastern Standard Time in New York, NY. This press release contains forward-looking statements, including statements relating to Am
11/24/15 - Background: Unipharm's decision over Sanofi may change patent realm [Jerusalem Post (Israel)]
Lod District Court Judge Ofer Groskopf precedent-setting ruling in favor of Unipharm and against Sanofi could shift the balance of economic risk of overly aggressive claiming of new patents in the patent arena from generic drug competitors to drug developers. The decision by Groskopf, known as an expert in such matters, was issued in late October,
11/24/15 - Bharat Book Bureau: Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2015
This report "Biosimilar- Competitive Landscape and Market& Pipeline Analysis, 2015" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players.
11/24/15 - Circassia Pharmaceuticals Wins Approval For FLIXOTIDE pMDi Equivalent
LONDON- Circassia Pharmaceuticals PLC on Tuesday said its fluticasone propionate pressurised metered dose inhaler generic equivalent of GlaxoSmithKline's FLIXOTIDE pMDI for the prophylactic treatment of asthma has received a stamp of approval from the UK's Medicines and Healthcare Products Regulatory Agency. "Achieving this positive outcome is a..
11/24/15 - Impax Launches Generic Version of Avodart (Dutasteride) Capsules, 0.5 mg
HAYWARD, Calif., No. 24, 2015/ PRNewswire/ Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. This is the 13 th generic product launched in 2015 by Impax's generic d
11/24/15 - India : Indian company wins USFDA approval for Sildenafil Tablets [TendersInfo (India)]
Hyderabad- based maker of generic drugs and active pharmaceutical ingredients, Aurobindo Pharma, has won final approval from the US Food& Drug Administration for the manufacturing and marketing of Sildenafil Tablets, 20 mg. The sanctioned ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product REVATIO Tablets 20 mg
11/24/15 - Intellipharmaceutics to Present at the LD Micro Main Event
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the LD Micro Main Event on December 2, 2015. The presentation may be accessed.
11/24/15 - Mylan Launches Generic FazaClo Orally Disintegrating Tablets
HERTFORDSHIRE, England and PITTSBURGH, Nov. 24, 2015/ PRNewswire/ Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo . Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for th
11/24/15 - Samsung accelerates marketing efforts in bio business [Korea Times]
The Samsung Group is stepping up efforts to carve out a larger share of the global biopharmaceutical market. According to industry sources, Samsung BioLogics, which manufactures pharmaceutical goods on consignment, will dedicate its third plant in Incheon this month. Samsung BioLogics has contracts with multinational giants, including Brystol-Myers
11/23/15 - $160B deal to combine Pfizer and Allergan raises outcry
A $160 billion deal announced Monday to merge Pfizer and Allergan and create the world's biggest drug company renewed the outcry in Washington over "inversions," in which U.S. corporations combine with companies overseas to lower their tax bill. In what would be the biggest inversion ever, New York- based Pfizer could save hundreds of millions in U
11/23/15 - CHMP recommends Samsung Bioepis' Enbrel biosimilar for EU approval [Seven Days (United Arab Emirates)]
The European Medicines Agency's Committee for Medicinal Products for Human Use has given a positive opinion recommending approval of Samsung Bioepis' Benepali, an investigational treatment developed as a biosimilar version of Amgen's Enbrel arthritis drug. Samsung Bioepis is the joint venture between Samsung Biologics and Biogen.
11/23/15 - Companies Venture into Global Biosimilar Market for Cost-effective Strategies: MarketResearchReports.Biz
The report, titled " Global& USA BioSimilar Market Analysis To 2021; BioBetters, Erythropoietin, Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Anti-Tumor Necrosis Factor, Monoclonal Antibodies, Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations And Strategic Outlook", reveals the statistical details of the glo
11/23/15 - Generic Drug Manufacturing Plant Project Report - One of the Biggest Market Drivers is an Increasing Global Pharmaceutical Spending Trend Towards...
Generic Drug Manufacturing Plant Project Report- One of the Biggest Market Drivers is an Increasing Global Pharmaceutical Spending Trend Towards Generics. By a News Reporter-Staff News Editor at Pharma Business Week Research and Markets has announced the addition of the "Generic Drug Manufacturing Plant Project Report: Industry Trends, Manufactur
11/23/15 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 58259) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting on the reauthorization of the Biosimilar User Fee Act for FY2018 through FY2022. LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, Section B and C of the Great Room, Room 1503, Silver Spring, Md.. CONTACT: Sandra Benton
11/23/15 - Lee Pharma to appear for fresh hearing on compulsory licence [Global Data Point]
The London- headquartered AstraZeneca holds the patent for saxagliptin.&# x0D;. So far, India has granted only one CL to domestic generic manufacturer Natco to produce the low-cost version of Bayer AG's kidney and liver cancer drug Nexavar, in 2012. "We are not at all apologetic about the CL issued to Natco, as it was well deserved.
11/23/15 - Mylan Launches Generic GLUCOTROL XL Tablets
By a News Reporter-Staff News Editor at Pharma Business Week Mylan N.V. announced the U.S. launch of Glipizide Extended-release Tablets, 5 mg and 10 mg, the generic version of Pfizer's GLUCOTROL XL. Glipizide Extended-release Tablets, 5 mg, and 10 mg, had U.S. sales of approximately $70.7 million for the 12 months ending September 30, 2015, accor
11/23/15 - Mylan Launches Generic Viramune XR Extended-Release Tablets, 100 mg
By a News Reporter-Staff News Editor at AIDS Weekly Mylan N.V., announced the U.S. launch of Nevirapine Extended-release Tablets, 100 mg, the generic version of Boehringer Ingelheim's Viramune XR. Nevirapine Extended-release Tablets, 100 mg, had U.S. sales of approximately $67 thousand for the 12 months ending Sept. 30, 2015, according to IMS Hea
11/23/15 - Perrigo acquires US rights to drug line for $380M
Over-the-counter and prescription drug maker Perrigo is acquiring the U.S. rights to an AstraZeneca drug line for Crohn's disease for $380 million. Dublin- based Perrigo, which has its North American headquarters in Allegan, said today that it will acquire Entocort, or budesonide, prescription capsules as well as the authorized generic capsules mar
11/23/15 - Perrigo Furthers Rx "Extended Topicals" Strategy With The Acquisition Of Leading Gastrointestinal Product Entocort
Perrigo Company plc announced today that it will acquire Entocort capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals within the U.S. from AstraZeneca plc for $380 million. Perrigo Chairman and CEO Joseph C. Papa commented, "We are extremely excited to acquire Entocort from a world-class organization such as
11/22/15 - India : Acquisition to expand Take Solutions' market to over $30 billion [TendersInfo (India)]
Chennai- based expert in life sciences and Supply Chain Management., Take Solutions, has inked a definitive deal to acquire Bengaluru-based life-sciences service company Ecron Acunova, for Rs.115 crore. The acquisition will make Take Solutions an expert in biosimilars, regenerative medicine and diagnostic imaging agents space, which are emerging gr
11/22/15 - Purchase with the delivery of cancer drugs, generic drugs, dressings for hospital pharmacies holy cross cancer center in kielce. [TendersInfo (India)]
Contract notice: Purchase with the delivery of cancer drugs, generic drugs, dressings for hospital pharmacies holy cross cancer center in kielce. The contract is for the purchase with the delivery of cancer drugs, generic drugs, dressings for Hospital Pharmacies Holy Cross Cancer Center in Kielce in accordance with Package 1: antibiotic.
11/22/15 - Switzerland : Regulatory submission for Sandoz proposed biosimilar pegfilgrastim accepted by the FDA [TendersInfo (India)]
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration has accepted its Biologics License Application under the 351 pathway for its proposed biosimilar to Amgen's US-licensed Neulasta - a recombinant human granulocyte colony-stimulating factor. Sandoz is seeking approval for the s
11/20/15 - Acerus Reports Approval of ESTRACE Generic in Canada
Acerus Pharmaceuticals Corporation today reported that Health Canada has granted a Notice of Compliance for a generic version of ESTRACE . Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
11/20/15 - Advantexe Launches Industry-First Biosimilar Pharmaceutical Business Simulation [Daily Star, The (Lebanon)]
-Advantexe Learning Solutions today announced the launch of an industry-first Biosimilar pharmaceutical business simulation that teaches business leadership and business acumen skills to organizations working on and launching biosimilar products. As the world of healthcare and specifically pharmaceuticals continues to evolve, so do the training...
Articles(s): 1 - 25 of 45     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement